Canada Markets closed

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8453+0.0853 (+11.22%)
At close: 04:00PM EDT
0.8600 +0.01 (+1.74%)
After hours: 06:45PM EDT

Applied Therapeutics, Inc.

545 Fifth Avenue
Suite 1400
New York, NY 10017
United States
212 220 9226
https://www.appliedtherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees34

Key Executives

NameTitlePayExercisedYear Born
Dr. Shoshana Shendelman Ph.D.Chair of the Board of Directors, Founder, Pres, CEO & Sec.588.47kN/A1979
Dr. Riccardo Perfetti M.D., Ph.D.Chief Medical Officer792.25kN/A1960
Mr. Chids MahadevanSr. VP of Fin. & Interim Principal Financial OfficerN/AN/A1970
Mr. Steven OrtegaChief Accounting OfficerN/AN/A1986
Mr. Adam HansardChief Commercial OfficerN/AN/A1976
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Corporate Governance

Applied Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 9. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.